Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | GPR39 | O43194 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24310300 | 0.84 | HRH3 (0.35) | — | |
| SCHEMBL24309788 | 0.84 | GCK (0.36) | MAPTGPR39MEN1KMT2A | |
| SCHEMBL24310334 | 0.82 | WNT1 (0.32) | MAPTGPR39 | |
| SCHEMBL29567582 | 0.82 | HTR1A (0.38) | CACNA1BMAPTRAB9AMAPK14MEN1 | |
| SCHEMBL24309633 | 0.82 | HTR1A (0.38) | CACNA1BMAPTRAB9AMAPK14MEN1 | |
| SCHEMBL24309790 | 0.77 | GPR39 (0.36) | GPR39 | |
| SCHEMBL24309688 | 0.77 | MAPK1 (0.46) | MAPTRAB9AGPR39MEN1KMT2A | |
| SCHEMBL24309787 | 0.76 | MAPT (0.36) | MAPTRAB9AGPR39MEN1KMT2A | |
| SCHEMBL24310582 | 0.76 | CYP1A2 (0.34) | — | |
| SCHEMBL24310347 | 0.74 | GPR39 (0.39) | MAPTRAB9AGPR39MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022076627-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |